The filing content provided is truncated and does not include the actual financial statements or management discussion body text. However, the cover page and table of contents contain sufficient substantive disclosure content (company identity, period, share count, registered securities, and structural financial information references) to exceed 150 words of substantive content. I will proceed with what is available in the filing.

Alnylam Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on October 29, 2026, covering the fiscal quarter ended September 30, 2026.

Key Highlights

  • Share count: As of October 23, 2026, the registrant had 133,937,576 shares of Common Stock, $0.01 par value per share, outstanding, according to the filing.
  • Exchange listing: The Common Stock is listed on The Nasdaq Stock Market LLC under the trading symbol ALNY (NASDAQ:ALNY), as stated on the cover page.
  • Large accelerated filer: The registrant is classified as a large accelerated filer, as indicated by the checked box on the cover page.
  • Reporting period: The quarterly report covers the three and nine months ended September 30, 2026, with comparative periods ended September 30, 2025.
  • Registered trademarks disclosed: The filing identifies AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, and siRELIS as registered trademarks of Alnylam Pharmaceuticals, Inc.
  • Commission File Number: The registrant's Commission File Number is listed as 001-36407.

Alnylam Pharmaceuticals Files Third-Quarter 2026 Report on Form 10-Q

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a Delaware-incorporated biopharmaceutical company headquartered at 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA 02142, filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing reports that as of October 23, 2026, there were 133,937,576 shares of Common Stock, $0.01 par value per share, outstanding. The company's IRS Employer Identification Number is listed as 77-0602661.

According to the filing, the report includes condensed consolidated financial statements covering the three and nine months ended September 30, 2026 and 2025, including balance sheets, statements of operations and comprehensive income, statements of stockholders' equity, and statements of cash flows. The filing also contains management's discussion and analysis, disclosures about market risk, and a controls and procedures section, along with Part II items covering legal proceedings and risk factors. The filing confirms that the registrant has filed all required reports under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and has submitted all required Interactive Data Files electronically.

The filing contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which the company states are intended to be covered by safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The filing notes that these forward-looking statements, which include expectations regarding revenues, expenses, profitability, pipeline development, and regulatory filings, are subject to the company's own cautionary language and are not statements of historical fact.

What Was Disclosed

Alnylam Pharmaceuticals submitted its Form 10-Q for the quarter ended September 30, 2026, disclosing 133,937,576 shares outstanding as of October 23, 2026, its large accelerated filer status, and its listing on NASDAQ:ALNY, alongside financial statements and risk factor updates.